Unlike other studies for the ArtAssist® device, these researchers examined the effects of intermittent pneumatic compression (IPC)
therapy on PAD patients suffering from infrapopliteal diffuse or multiple segmental lesions and who were at risk of amputation.
Patients were separated into study (n=23) and control (n=8) groups and were given the following tests before and after the study period:
- 6-minute walking test to examine claudication distance.
Results: duration and initial and absolute claudication distances significantly increased in study group
- Transcutaneous oxygen tension (TcPO2).
Results: significantly increased in distal end of target limb after IPC therapy
- Quality of Life (Short-Form 36 questionnaire):
Results: significant changes in physical functioning, physical and emotional role functioning, bodily pain, and general and mental health after IPC therapy
The study group received ArtAssist® device therapy for three months, three hours per day. The ArtAssist® device rapidly compresses the foot, ankle, and calf at 120 mmHg approximately every 17 seconds. The rapid inflation and deflation of the cuffs is instrumental to the arteries’ vasodilation.
The significant improvements in walking distance, oxygen levels, and quality of life show both medical and lifestyle benefits for patients who are not candidates for surgical intervention.
To read more about the clinical trials conducted with ArtAssist®…The Arterial Assist Device®, please visit the Clinical Studies Page.
- Using a Pneumatic Compression Device for Lower and Upper Extremity…
- Compressing Ischemic Limbs and Why It’s Beneficial
- “Walking Therapy and Pneumatic Compression: The Natural Cures for Poor…
- Dr. Paul van Bemmelen talks about treating PAD without surgery…
- Help for your arteries with the ArtAssist® pneumatic compression pump